BE1002134A5 - RECOMBINANT AVIPOX VIRUS. - Google Patents

RECOMBINANT AVIPOX VIRUS. Download PDF

Info

Publication number
BE1002134A5
BE1002134A5 BE8800978A BE8800978A BE1002134A5 BE 1002134 A5 BE1002134 A5 BE 1002134A5 BE 8800978 A BE8800978 A BE 8800978A BE 8800978 A BE8800978 A BE 8800978A BE 1002134 A5 BE1002134 A5 BE 1002134A5
Authority
BE
Belgium
Prior art keywords
avipox
avipox virus
source
recombinant avipox
vertebrate
Prior art date
Application number
BE8800978A
Other languages
French (fr)
Inventor
Enzo Paoletti
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1002134(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of BE1002134A5 publication Critical patent/BE1002134A5/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention fournit un procédé pour induire une réponse immunoligique vis-à-vis d'un pathogène chez un vertébré en inoculant le vertébré à l'aide d'un virus avipox recombinant de synthèse modifié par la présence, dans une région non essentielle du génome de l'avipox, l'ADN provenant de n'importe quelle source qui code pour un antigène du pathogène et exprime cet antigène. La présente invention fournit en outre un virus avipox recombinant de synthèse modifié par l'insertion, à l'intérieur de celui-ci, d'ADN provenant de n'importe quelle source, et en particulier provenant d'une source non avipox, dans une région non essentielle du génome de l'avipox.The present invention provides a method for inducing an immunoligic response to a pathogen in a vertebrate by inoculating the vertebrate using a synthetic recombinant avipox virus modified by the presence in a nonessential region of the avipox genome, DNA from any source that codes for and expresses an antigen of the pathogen. The present invention further provides a synthetic recombinant avipox virus modified by the insertion therein of DNA from any source, and in particular from a non-avipox source, into a nonessential region of the avipox genome.

BE8800978A 1987-08-28 1988-08-29 RECOMBINANT AVIPOX VIRUS. BE1002134A5 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9071187A 1987-08-28 1987-08-28
US11033587A 1987-10-20 1987-10-20
US18605488A 1988-04-25 1988-04-25
US23439088A 1988-08-23 1988-08-23

Publications (1)

Publication Number Publication Date
BE1002134A5 true BE1002134A5 (en) 1990-07-24

Family

ID=27492413

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8800978A BE1002134A5 (en) 1987-08-28 1988-08-29 RECOMBINANT AVIPOX VIRUS.

Country Status (17)

Country Link
JP (3) JP3348156B2 (en)
KR (1) KR970011149B1 (en)
AR (1) AR241939A1 (en)
AT (1) AT408549B (en)
AU (2) AU2427588A (en)
BE (1) BE1002134A5 (en)
CH (2) CH679933A5 (en)
DE (4) DE10399032I1 (en)
DK (1) DK175904B1 (en)
FR (1) FR2621487B1 (en)
GB (1) GB2217718B (en)
IL (1) IL87581A0 (en)
IT (1) IT1229484B (en)
LU (2) LU90951I2 (en)
NL (4) NL195051C (en)
NZ (1) NZ225970A (en)
WO (1) WO1989003429A1 (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399032I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE3813093A1 (en) * 1988-04-19 1989-11-09 Immuno Ag RECOMBINANT PLASMIDE, METHOD FOR PRODUCING A RECOMBINANT AVIPOX VIRUS, RECOMBINANT AVIPOX VIRUS, AND USE THEREOF
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012684A1 (en) * 1988-06-24 1989-12-28 National Research Development Corporation Fowlpox virus non-essential regions
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
FR2668064B1 (en) 1990-10-23 1994-12-16 Transgene Sa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT TUMOR.
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
US5503834A (en) * 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
IE71643B1 (en) * 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5338679A (en) * 1991-01-08 1994-08-16 Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
KR100242671B1 (en) * 1991-03-07 2000-03-02 고돈 에릭 Genetically engineered vaccine strain
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
WO1992022641A1 (en) * 1991-06-14 1992-12-23 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
EP0575544A4 (en) * 1991-03-20 1997-05-21 Virogenetics Corp Malaria recombinant poxvirus vaccine
JPH06509235A (en) * 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション Infectious Bursal Disease Virus Recombinant Poxvirus Vaccine
ES2212795T3 (en) * 1991-08-26 2004-08-01 Baxter Healthcare S.A. VIRUSES OF THE VIRUELA DE LAS AVES DE RECOMBINANTE CORRAL.
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6497882B1 (en) 1992-01-13 2002-12-24 Syntro Corporation Recombinant swinepox virus
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6328975B1 (en) 1992-01-13 2001-12-11 Syntro Corporation Recombinant swinepox virus
US6127163A (en) * 1992-01-13 2000-10-03 Syntro Corporation Recombinant swinepox virus
US6251403B1 (en) 1992-01-13 2001-06-26 Syntro Corporation Recombinant swinepox virus
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
DE69333728T2 (en) * 1992-01-13 2006-08-31 Virogenetics Corp. Redoxic poxvirus as a vaccine against the Marek disease virus.
JPH08501452A (en) * 1992-09-21 1996-02-20 ビアジーン，インコーポレイティド Recombinant retrovirus vector for FELV and / or FIV
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
WO1994019014A1 (en) * 1993-02-26 1994-09-01 Syntro Corporation Recombinant fowlpox virus s-fpv-043 and uses thereof
AU727278B2 (en) * 1993-02-26 2000-12-07 Syntro Corporation Recombinant fowlpox viruses and uses thereof II
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (en) * 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (en) 1997-12-01 1999-06-22 Lintec Corp Cover tape for carrying chip body and sealing structure
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
JP2002533124A (en) 1998-12-31 2002-10-08 カイロン コーポレイション Improved expression of HIV polypeptide and generation of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2374346C (en) 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibitors of memapsin 2 and use thereof
CZ303468B6 (en) 2000-02-23 2012-10-03 Smithkline Beecham Biologicals S. A. Immunogenic mixture and pharmaceutical mixture
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002080982A2 (en) 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
BR0207761A (en) * 2001-03-08 2006-01-31 Akzo Nobel Nv Use of a live recombinant leporipox virus, vaccine, and live recombinant leporipox virus
JP4499311B2 (en) * 2001-04-27 2010-07-07 シャープ株式会社 Broadcast receiving terminal
JP2005504513A (en) 2001-05-09 2005-02-17 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of prostate cancer
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2452119C (en) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
ES2405405T3 (en) 2001-12-17 2013-05-31 Corixa Corporation Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease
WO2004062599A2 (en) 2003-01-06 2004-07-29 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1628680B1 (en) 2003-05-15 2012-10-24 Novartis Vaccines and Diagnostics, Inc. Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
KR101359930B1 (en) 2004-09-22 2014-02-12 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic composition for use in vaccination against staphylococcei
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
BRPI0708865A8 (en) 2006-03-14 2019-01-22 Univ Oregon Health & Science methods to produce an immune response to tuberculosis
AU2008221383B2 (en) 2007-02-28 2012-09-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
WO2009049351A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Construct system and uses therefor
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
CN102713629B (en) 2009-11-20 2016-02-24 俄勒冈健康科学大学 For detecting the method for m tuberculosis infection
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
CN107837394A (en) 2011-06-24 2018-03-27 埃皮托吉尼西斯有限公司 Pharmaceutical composition as the combination of the carrier comprising selection of antigen specific immune conditioning agent, vitamin, tannin and flavonoids
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
ES2752190T3 (en) 2012-09-14 2020-04-03 Us Health Brachyury protein, adenoviral vectors encoding Brachyury protein and their use
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
MX2015014568A (en) 2013-04-17 2016-12-02 Genzyme Corp Compositions and methods for treating and preventing macular degeneration.
EP3010522B1 (en) 2013-05-21 2021-01-20 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
KR102234695B1 (en) 2014-02-06 2021-04-02 젠자임 코포레이션 Compositions and methods for treating and preventing macular degeneration
WO2016044707A1 (en) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
WO2016172479A1 (en) 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
EP3294755B1 (en) 2015-05-13 2023-08-23 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3313863B1 (en) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US10917454B1 (en) 2019-08-01 2021-02-09 Rohde & Schwarz Gmbh & Co. Kg System and method for ATC voice quality assurance
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052002A2 (en) * 1980-11-10 1982-05-19 G.D. Searle & Co. Plasmid vectors, production and use thereof
EP0162757A1 (en) * 1984-04-25 1985-11-27 Transgene S.A. Vaccine for rabies and process for its preparation
WO1986005806A1 (en) * 1985-03-29 1986-10-09 National Research Development Corporation Infectious bronchitis virus spike protein
EP0216564A2 (en) * 1985-09-09 1987-04-01 Cetus Corporation Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
EP0227414A2 (en) * 1985-12-18 1987-07-01 Btg International Limited Newcastle disease virus gene clones
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0284416A1 (en) * 1987-03-27 1988-09-28 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
EP0314569A1 (en) * 1987-10-29 1989-05-03 Transgene S.A. Recombinant fowlpox virus, expression vectors for heterologous proteins, and vaccines for fowl derived from this virus
WO1989003879A1 (en) * 1987-10-23 1989-05-05 National Research Development Corporation Fowlpox virus promoters

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
WO1984002077A1 (en) * 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
EP0190254A4 (en) * 1984-07-05 1987-03-09 Genex Corp Cloned gene and method for making and using the same.
DD235669A1 (en) * 1985-03-26 1986-05-14 Akad Wissenschaften Ddr METHOD FOR PRODUCING A BLV-CODED HUEL PROTEIN
AU6170486A (en) * 1985-08-23 1987-02-26 Advanced Genetics Research Institute Defective viral vaccines
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
AU8075787A (en) * 1986-09-22 1988-04-07 Australian National University, The Recombinant poxviruses
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
DE10399032I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
WO1989012684A1 (en) * 1988-06-24 1989-12-28 National Research Development Corporation Fowlpox virus non-essential regions
CH682669A5 (en) * 1989-03-08 1993-10-29 Health Research Inc recombinant virus engineered to express a gene product in a host, corresponding methods and vaccine.
JP3895366B2 (en) * 1990-09-25 2007-03-22 キャンタブ ファーマシューティカルズ リサーチ リミティド Virus vaccine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052002A2 (en) * 1980-11-10 1982-05-19 G.D. Searle & Co. Plasmid vectors, production and use thereof
EP0162757A1 (en) * 1984-04-25 1985-11-27 Transgene S.A. Vaccine for rabies and process for its preparation
WO1986005806A1 (en) * 1985-03-29 1986-10-09 National Research Development Corporation Infectious bronchitis virus spike protein
EP0216564A2 (en) * 1985-09-09 1987-04-01 Cetus Corporation Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
EP0227414A2 (en) * 1985-12-18 1987-07-01 Btg International Limited Newcastle disease virus gene clones
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0284416A1 (en) * 1987-03-27 1988-09-28 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
WO1989003879A1 (en) * 1987-10-23 1989-05-05 National Research Development Corporation Fowlpox virus promoters
EP0314569A1 (en) * 1987-10-29 1989-05-03 Transgene S.A. Recombinant fowlpox virus, expression vectors for heterologous proteins, and vaccines for fowl derived from this virus

Also Published As

Publication number Publication date
DE3890874C5 (en) 2005-10-20
JP3348156B2 (en) 2002-11-20
LU90951I2 (en) 2003-01-15
GB2217718A (en) 1989-11-01
DK175904B1 (en) 2005-06-06
GB8908921D0 (en) 1989-08-02
NL300138I1 (en) 2004-02-02
ATA900788A (en) 1995-05-15
AU2427588A (en) 1989-05-02
IT8821772A0 (en) 1988-08-29
FR2621487A1 (en) 1989-04-14
NL300139I1 (en) 2004-02-02
AT408549B (en) 2001-12-27
DE3890874C2 (en) 2003-03-13
DK203689A (en) 1989-06-27
NL300138I2 (en) 2004-03-01
GB2217718B (en) 1992-05-20
JP2002186494A (en) 2002-07-02
JPH02500879A (en) 1990-03-29
DE10399032I1 (en) 2004-01-29
CH679933A5 (en) 1992-05-15
DE10299049I1 (en) 2004-07-01
NL195051C (en) 2003-07-01
NL300130I1 (en) 2003-09-01
NZ225970A (en) 1991-01-29
AU1628895A (en) 1995-08-17
AU690210B2 (en) 1998-04-23
NL8820679A (en) 1989-07-03
FR2621487B1 (en) 1991-10-18
IT1229484B (en) 1991-09-03
WO1989003429A1 (en) 1989-04-20
KR890701757A (en) 1989-12-21
LU91039I2 (en) 2003-11-05
CH679934A5 (en) 1992-05-15
NL300130I2 (en) 2005-11-01
JP2002348255A (en) 2002-12-04
JP3826055B2 (en) 2006-09-27
DK203689D0 (en) 1989-04-27
AR241939A1 (en) 1993-01-29
KR970011149B1 (en) 1997-07-07
DE10399031I1 (en) 2004-01-29
IL87581A0 (en) 1989-01-31

Similar Documents

Publication Publication Date Title
BE1002134A5 (en) RECOMBINANT AVIPOX VIRUS.
AR248044A1 (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
IT1278077B1 (en) METHODOLOGY TO REPRODUCE IN VITRO THE ACTIVITIES OF RNA-DEPENDENT RNA POLYMERASE AND OF TERMINAL NUCLEOTIDYLTRANSPHERASE CODED BY THE
PT733069E (en) PURIFIED PRIMATE CTLA-8 ANTIGENS AND RELATED REAGENTS
HUT73384A (en) Methods of typing hepatitis c virus and reagents for use therein
TNSN88004A1 (en) HEPATITIS B VIRUS SURFACE ANTIGENS AND HYBRID ANTIGENS CONTAINING THEM
DE69433301D1 (en) METHODS FOR INCREASING THE BIOLOGICAL ACTIVITY OF CHEMOKINES
HUP9900929A2 (en) Methods for retreatment of patients afflicted with hepatitis c using consensus interferon
UA40572C2 (en) Polypeptide containing truncated sequence of hepatitis c virus, isolated epitope, reagent for immunoanalysis to hepatitis c virus, method for identification of availability of antibodies (variants)
DK368588D0 (en) BINDING MOLECULES WITH A SIMPLE PLYPEPTID CHAIN
DK166087A (en) HTLV-III VIRUS PROTEIN, DNA SEQUENCE THAT CODES THEREOF, PROCEDURES FOR PRODUCING IT, PROCEDURE FOR DETECTING AIDS VIRUS AND ANTIBODIES AGAINST AIDS VIRUS
DK108589D0 (en) CHIMERARY ANTIBODIES AGAINST HUMANT CARCINOEMBRYONAL ANTIGEN AND DNA SEQUENCES CODING FOR SUCH ANTIBODIES
DK648689A (en) NON-A, NON-B HEPATITIS VIRUS THROUGH RNA, ITS CDNA, AND ITS VIRUS ANTIGEN PROTEIN
EA200000196A1 (en) UNIVERSAL BLOOD PLASMA
GB8601680D0 (en) Modification of plant viruses
EP0593290A3 (en) Core antigen protein of hepatitis C virus, and diagnostic method and kit using the same.
DE69433400D1 (en) NEW PROTEINS FROM PARASITIC WORMS
EP1013757A3 (en) Attenuated forms of bovine viral diarrhea virus
ATE285418T1 (en) HUMANIZED ANTIBODY SPECIFIC TO THE SURFACE ANTIGEN PRE-S1 OF HBV AND ITS PREPARATION
ATE162553T1 (en) MONOCLONAL ANTIBODIES AGAINST HEPATITIS C VIRUS
PT728015E (en) COMBINATORIAL POLYPEPTIDIC ANTIGENS
EA199700438A1 (en) INTERGENGAL AREAS OF THE BANANOE THRESHIP VIRUS
ES2069298T3 (en) SEQUENCES NO-A NO-B.
ATE132160T1 (en) METHOD FOR PURIFYING OUTER MEMBRANE PROTEIN FROM HAEMOPHILUS INFLUENZA
DE3580482D1 (en) MONOCLONAL ANTIBODIES AND IMMUNIZATION THEREFOR.

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *HEALTH RESEARCH INC.

Effective date: 20080829

CCRE Expiry of a supplementary protection certificate

Owner name: *HEALTH RESEARCH INC.

Free format text: PRODUCT NAME: VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/KENTUCKY/94 - VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/NEWMARKET/2/93 - ANATOXINE CLOSTRIDIUM TETANI; REGISTRATION NO/DATE: EU/2/03/038/00 20030307

Spc suppl protection certif: 2003C/022

Filing date: 20030901

Expiry date: 20080829

Extension date: 20130829

Effective date: 20130829

Free format text: product name: RCP FELV.; registration no/date: EU/2/02/031/001 20020311

Spc suppl protection certif: 2002C/024

Filing date: 20020904

Expiry date: 20080829

Extension date: 20130829

Effective date: 20080829

Free format text: product name: VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/KENTUCKY/94 - VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/NEWMARKET/2/93; registration no/date: EU/2/03/037/001 20030307

Spc suppl protection certif: 2003C/021

Filing date: 20030901

Expiry date: 20080829

Extension date: 20130829

Effective date: 20080829